SpeeDx Partners with Nepean Hospital to Commercialise Respiratory Virus Host Biomarker Assay
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has partnered with researchers from Nepean Blue Mountains Local Health District’s (NBMLHD) Nepean Hospital in an exclusive agreement to commercialise a host gene expression biomarker test for respiratory viral illness. Expression of the patented biomarker, IFI27, as discovered by NBMLHD Drs Anthony Maclean, Benjamin Tang and colleagues, is strongly correlated with disease progression in Influenza1 and COVID-19 patients2. The commercial assay will be positioned to support clinicians facing difficult triage or patient management decisions, supporting risk-based stratification of patients presenting with respiratory viral illness, including COVID-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109005432/en/
SpeeDx newly patented InSignia technology simplifies the measurement of gene expression and will underpin the creation of a simple, standardized biomarker test to support management of patients with respiratory viral illness. (Photo: Business Wire)
“Host biomarkers are important indicators of a patient’s response to an infection,” said Professor Maclean, from the Nepean Hospital’s Intensive Care Unit. “Markers linked to viral specific immune responses, such as IFI27 – an interferon stimulating gene – are particularly informative. When they get switched on, it tells all the other immune cells to come and fight the virus. Levels of this specific marker, measured in the blood, have been shown to be directly correlated to progression of respiratory viral illness.”
The SpeeDx biomarker test utilises newly patented InSigniaTM technology that enhances the measurement of gene expression and is designed to run on standard laboratory equipment, allowing for expedited development and rapid adoption in high- and low-throughput hospital settings.
“The availability of a simple diagnostic test that can accurately differentiate viral from bacterial causes of pulmonary disease, using a single-gene host biomarker, would transform patient management,” said Dr. Charles Cartwright, SpeeDx VP of Scientific Affairs. “Coupled with a pathogen detection assay and other disease indicators, this test can not only stratify patients based on risk of adverse disease progression, changes in the level of biomarker over time can inform more accurate prognoses and guide ongoing patient management decisions.”
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
About Nepean Blue Mountains Local Health District
Nepean Blue Mountains Local Health District is well placed to draw on over 100 years of continuously caring for the community, conducting research and delivering innovation. The Nepean Hospital Intensive Care Unit is part of NBMLHD’s 5,700-strong staff. Being on the frontline of health means NBMLHD has a focus on practical solutions that deliver maximum impact to the health and wellbeing of patients and their families.
- Tang BM et al. Eur Respir J. 2017 Jun 15;49(6):1602098.
Australia, New Zealand and Europe
Madeline O’Donoghue - SpeeDx
+61 406 582 808
Rick Roose - RCI Healthcare Public Relations
+1 415 202 4445
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Northern Data AG Commissions First Data Center in the Netherlands25.11.2020 14:11:00 CET | Press release
Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87), a leading provider of High-Performance Computing (HPC) solutions, is commissioning its latest HPC data center near Maastricht. This new facility will entail one of the largest GPU clusters worldwide and will be the Company's first data center location in the European Union. The Company will begin installing the first hardware for its GPU-based Distributed Computing Cluster from the beginning of December. The GPU cluster is one of Northern Data AG's most significant expansion steps and is expected to be scaled up by the end of Q1/2021 to achieve computing power of 404 Petaflops (FP64). With this level of power, it will be one of the largest GPU clusters of its kind worldwide. The world's most powerful supercomputer, Japan's Fugaku, has a computing capacity of 415 Petaflops. As CEO Aroosh Thillainathan commented: "With the smooth and rapid expansion of our GPU cluster, now including our first European location, we are moving to meet the
LexFinance Announced a Favorable Partial Award in a US$ 28 Billion Arbitration Against Brazil and for the Benefit of Petrobras25.11.2020 14:00:00 CET | Press release
LexFinance announced a favorable partial award in a US$ 28 billion arbitration against Brazil and for the benefit of Petrobras. The claim has been filed by a minority shareholder of Petrobras against the Brazilian Government for the economic losses suffered by Petrobras due to corruption practices disclosed in the Car Wash investigation and caused by the abuse of power of the Brazilian Government as controlling shareholder of Petrobras. The partial award recognized the arbitrability of the dispute, that the Brazilian Government is subject to the arbitration clause and the standing of the claimant funded by LexFinance to act on behalf and for the benefit of Petrobras. If the damages are confirmed in the last phase of the arbitration expected to conclude during 2021, the Brazilian Government will have to compensate Petrobras for losses currently estimated at US$ 28 billion. In addition, according to article 246 of the Brazilian Corporate Law, it will have to pay to the claimant funded by
Last and Final Victory for Sisvel Before the German Federal Supreme Court (BGH) In the Sisvel vs Haier Cases25.11.2020 13:29:00 CET | Press release
Yesterday the German Federal Supreme Court heard the oral arguments in another patent infringement case between Sisvel and Haier regarding Sisvel’s request for injunctive relief for infringement of cellular standard essential patents (SEPs) it owns. The decision rendered yesterday marks the final decision regarding Haier’s infringement of Sisvel’s European patent EP 1 264 504 (“EP 504”), and the related FRAND defense after a 6 year long legal dispute. Prior to this verdict, the BGH (1) confirmed the German part of Sisvel’s EP 504 valid on April 28, 2020, (2) confirmed the German part of Sisvel’s EP 0 852 885 B1 (“EP 885”) valid on March 10, 2020, and (3) reversed the Düsseldorf Court of Appeal’s 2017 decision that wrongly considered Haier a willing licensee on May 5, 2020. In the motivation of the BGH May 2020 decision, it provided helpful guidance on certain aspects of the FRAND negotiation process (see https://www.sisvel.com/news-events/news/clarifications-on-licensing-of-standard-es
Advanced Technology Research Council Announces ‘ASPIRE’ – to Drive the Creation of Future Transformative Technologies25.11.2020 12:22:00 CET | Press release
The newly established Advanced Technology Research Council (ATRC) has today announced its plans to drive the creation of future transformative technologies with the launch of its dedicated technology programme management pillar, ASPIRE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201125005562/en/ His Excellency Faisal Al Bannai, Secretary-General of Advanced Technology Research Council (Photo: AETOSWire) ASPIRE works in consultation with cross-sector industry stakeholders to frame problem statements that can be solved through research and development. By defining the problem, setting milestones, and monitoring the progress of the projects, ASPIRE facilitates a clear path from ‘lab to market.’ ASPIRE will make impactful decisions related to the selection of research partners and the allocation of funding. It will ensure that its R&D priorities align with Abu Dhabi and the UAE's broader development goals. ASPIRE will also l
Celltrion completes enrolment for global Phase II clinical trial with COVID-19 treatment candidate CT-P5925.11.2020 12:13:00 CET | Press release
Celltrion Group today announced enrolment completion of 327 patients with mild-to-moderate symptoms of SARS-CoV-2 infection in the global Phase II clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate. Celltrion anticipates submission for emergency use authorisation (EUA) to the Korean Ministry of Food and Drug Safety (MFDS), conditional on results from the global Phase II pivotal trial. The global Phase II clinical trial is a randomised, double-blind, placebo-controlled and parallel-group trial designed to evaluate the efficacy and safety of CT-P59 in combination with standard of care in patients with SARS-CoV-2 infection. The trial enrolled 327 patients with mild-to-moderate symptoms of COVID-19 across three groups (placebo, low concentration, high concentration) and Celltrion is set to obtain the results for global Phase II trial. In addition, Celltrion plans to initiate a global Phase III clinical trial in more than 10 countries in order to obtain more
iHeartMedia and Podimo Partner to Translate and Adapt Widely Popular Podcasts For Listeners Globally25.11.2020 12:00:00 CET | Press release
iHeartMedia, the No. 1 audio company in America and the No. 1 podcast publisher globally, and European podcast platform Podimo today announced a strategic partnership to translate and adapt popular podcasts across the globe in different languages, introducing these podcasts to hundreds of millions of new listeners. The partnership will kick off with the widely popular true crime podcast “Forgotten: Women of Juárez” (Olvidadas: Muertes de Juárez) about femicides in Mexico’s most dangerous city in three languages: Spanish, German and Danish. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201125005440/en/ In one of 2020’s most intimate and shocking true crime podcasts, “Forgotten: Women of Juárez,” from iHeartMedia and Unusual Productions, hosts Mónica Ortiz Uribe and Oz Woloshyn investigate theories surrounding the disappearance of hundreds of young women along the Mexican border city of Juárez. Some are tragically found with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom